Maintenance therapy after stem cell transplant for NK/T-cell lymphoma
Part of Cancer clinical trials.
This trial tests two drugs, selinexor and azacitidine, given after a stem cell transplant to help prevent the lymphoma from coming back. The goal is to see if this combination is safe and effective as a maintenance treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with NK/T-cell lymphoma.
- You have already had a stem cell transplant (from any donor type).
- Your blood counts are within a certain range (ANC at least 1.0 and platelets at least 75).
- You are not currently experiencing severe graft-versus-host disease (GVHD) or other serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three chemotherapy drugs given before a stem cell transplant to treat NK/T-cell lymphoma. The goal is to see if this conditioning regimen helps the transplant succeed and reduces side effects.
This Phase 2 study tests whether a medicine called selinexor, combined with COPL, can shrink newly diagnosed NK/T-cell lymphoma that is advanced (stage III–IV). It also looks at how safely the treatment works in people who have good enough blood counts and organ function.
This trial tests a combination of three drugs (selinexor, pegaspargase, and dexamethasone) for people with newly diagnosed NK/T-cell lymphoma. It aims to see if this treatment can shrink tumors and be safe.
This study tests two drugs, selinexor and venetoclax, given after a stem cell transplant to keep high-risk leukemia or myelodysplastic syndrome from coming back. The goal is to see if this maintenance therapy is safe and effective for patients.
This trial is testing a combination of three treatments for a rare type of lymphoma called NKTCL that has come back or not responded to prior therapy. The treatments include a pill (selinexor), an immune-boosting drug (anti-PD-1 antibody), and a chemotherapy combination (P-GemOx). The goal is to see if this combination can help control the lymphoma and improve outcomes.
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
Hear when a new NK T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.